I'd be pleasantly surprised if Israel and Europe approvals led to sustained share price growth
Any sign that IXC is on track to close EVOLVE trial earlier than scheduled (Q1 CY2025) - by for e.g. recruiting all 250 patients by Q3 CY2023 - could be a strong catalyst for share price growth. Having a sizeable volume of options expiring next year certainly incentivises some acceleration of timelines. Let's see!
IXC Price at posting:
54.5¢ Sentiment: Buy Disclosure: Held
